All patients identified in the neonatal screening programme for congenital hypothyroidism in Northern Ireland between 1983 and 1993 were reviewed. 131 infants were recalled because of TSH elevation of whom 85 proved to have true permanent congenital hypothyroidism, while 44 had transient TSH elevation and 2 cases died before the diagnosis could be confirmed. TSH elevation at presentation was milder in the transient group and these infants were more likely to be unwell and/or suffering from congenital malformation.
year Myelomeningocele was present in 6 infants, congenital heart disease in 4, Downs Syndrome in 2 and prematurity in 2. Within this group, the median serum free thyroxine at recall was 19.1 pmol/l (range <2-28.4 pmol/l) and median serum TSH was 14.5 mu/l (range <5->320 mu/l).
DISCUSSION
The In addition, compared to infants with permanent CH, this group had an equal male to female ratio and a significantly higher free thyroxine and lower serum TSH level at recall. All neonates who are started on thyroxine for CH and maintain normal thyroid function tests on follow-up should have their diagnosis confirmed by withdrawing treatment after 2 years of age and following up thyroid function. As previously shown 10, 11 this is particularly relevant for ill or pre-term infants with less severe abnormalities of thyroid function before thyroxine replacement.
